PCRX Q1 2018 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M+7.7% YoY

Gross Profit

$52M69.3% margin

Operating Income

-$7M-9.3% margin

Net Income

-$11M-14.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$8M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$622M

Total Liabilities

$344M

Stockholders' Equity

$279M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$69M	+7.7%
Gross Profit	$52M	$45M	+15.7%
Operating Income	-$7M	-$14M	+50.6%
Net Income	-$11M	-$20M	+46.2%

Revenue Segments

EXPAREL

$74M100%

DepoCyt(e) and Other Products

$253,0000%